PW
VRTX icon

Paladin Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Paladin Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,074
Closed -$480K – 142
2026
Q1 		$480K Sell
1,074
-101
-9% -$47.1K 0.33% 89
2025
Q4 		$533K Sell
1,175
-62
-5% -$26.7K 0.36% 96
2025
Q3 		$484K Sell
1,237
-3
-0.2% -$1.25K 0.35% 95
2025
Q2 		$552K Buy
+1,240
New +$571K 0.43% 92

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Paladin Wealth's VRTX Position: Q2 2026 in Review

Paladin Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,074 shares — an estimated $480K sold.

Paladin Wealth first reported a position in VRTX in Q2 2025 and held it in 4 quarters. The position peaked at $552K in Q2 2025. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Paladin Wealth reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Paladin Wealth sold 1,074 Vertex Pharmaceuticals shares in Q2 2026, an estimated $480K.
  • Paladin Wealth first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Paladin Wealth's Vertex Pharmaceuticals position peaked at $552K in Q2 2025.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Paladin Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.